Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (June 2010)
37 slides from Lisata Therapeutics's investor presentation, Jun 2, 2010
Slide 1: NeoStem, Inc. Investor Presentation June 2010
NEOSTEM, INC. (“NBS”) Investor Presentation June 2010
Slide 2: Forward-Looking Statement
Forward-Looking Statement Included in this presentation are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, ‘as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors wh
Slide 3: 2009 – YTD 2010 Accomplishments
2009 — YTD 2010 Accomplishments « Unprecedented collaboration with Vatican's Pontifical Council for Culture » Advance adult stem cell understanding, research and therapeutic applications = Significantly strengthened adult stem cell therapeutic platform = Exclusive worldwide license for stem cell tec
Slide 4: 2009 – YTD 2010 Accomplishments (Cont)
: 2 2009 — YTD 2010 Accomplishments (Cont) Sy Ss « Evolved into an international biopharma company with operations in China « Built platform and infrastructure in China to establish partnerships to commercialize stem cell applications and generate near-term revenues « Signed strategic partnerships w
Slide 5: Company Overview
Company Overview NeoStem, Inc. (NYSE Amex: NBS) Suzhou Erye - Pharmaceuticals U.S. Stem Cells China Stem Cells 100% 100% 51% interest acquired ‘October 30, 2008 Summary Profile Ticker NBS (AMEX) 2010 Trading Range $1.26 - $3.50 Market Cap‘ $146 million Corporate Headquarters nyc Pharmaceutical Subsi
Slide 6: Pharmaceuticals - China
Pharmaceuticals - China
Slide 7: Profitable & Growing
— Profitable & Growing = Vertically-integrated manufacturer of generic antibiotic Rx products and APIs = 8 cGMP-certified production lines «= Extensive distribution network throughout PRC = No significant customer concentration = 60% of current drug portfolio covered by insurance (expected to grow)
Slide 8: Diversified Product Portfolio
Diversified Product Portfolio No single drug accounting for >10% of sales Top Ten Drugs in 2009 (52.6% of Total Sales) Drugs % of Sales Acetylspiramycin 75% Oxacillin Sodium 7.2% Mezlocillin Sodium for injection 6.9% Amoxicillin Sodium & Sulbactam Sodium for injection 6.5% Cefoperazone Sodium & Sulb
Slide 9: Large Chinese Pharmaceutical Opportunity
Large Chinese Pharmaceutical Opportunity = China announced $124 billion budget to improve healthcare system in 2009-11 = Provide universal medical service to China’s 1.3 billion population = New Rural & Urban Cooperative Medical Insurance System — at least 90% of population will be covered by 2011 =
Slide 10: Significant Manufacturing Capacity Expansion
2 Significant Manufacturing Capacity Expansi = New facility completed in 2009 + Penicillin sterile API facility for solvent crystallization and freeze dried raw material drugs with two cGMP lines approved = 2010 / 2011 targets = Penicillin powder for injection facility « Cephalosporin powder for inj
Slide 11: Platform to Drive Sustainable Growth
Platform to Drive Sustainable Growth = Current pipeline of 7 Rx drugs « Two pending launch, two pending approval, three in active development « External growth strategy « Enhance R & D activities in China and the U.S. + In-license drugs with proven efficacy & efficacy that leverages new facility = E
Slide 12: Adult Stem Cell Initiatives U.S. & China
Adult Stem Cell I U.S. & China iatives 12
Slide 13: Two main types of stem cells
Two main types of stem cells = Adult Stem Cells - isolated from adult tissues Stem Cell Background Act as tissue repair and maintenance system Multipotent Reduces risk of immune rejection Successful use in human therapies (i.e. bone marrow transplant) for 40 years * Embryonic Stem Cells — isolated f
Slide 14: Stem Cell Market Opportunity
Stem Cell Market Opportunity Attractive market with both near- and longer-term opportunities « Fragmented market with significant barriers to entry = Commercial opportunities already being realized ex-U.S. = Expedited clinical and regulatory pathways compared to U.S. = Regulated by the Ministry of H
Slide 15: NeoStem and Vatican's Pontifical Council
NeoStem and Vatican’s Pontifical Council Planned Joint Initiatives = Launch International Conference at the Vatican in 2011 = Adult Stem Cell research, including VSEL™ Technology, with thought leaders from all over the world * Derive potential financial resources from multiple sources to support VSE
Slide 16: Pioneer in adult stem cell banking
joneer in adult stem cell bankin: * Recurring revenue stream * Minimally invasive procedure (“apheresis”) * Growing network in major metropolitan areas = Expand to ten centers by end of 2010 * East and West Coast processing locations through PCT B. Adult stem cell research * Global Research HQ — Cam
Slide 17: Expansive Adult Stem Cell Therapies
<' Expansive Adult Stem Cell Therapies s+ ~ Collection Process ——ie vsciiiggsbiaiiomm = Accelerated skin wound = Low-dose, short course, = Identification, isolation, and healing with stem cells and GCSF induction of stem use of very small embryonic- fibrin cell mobilization like stem cells (VSEL™ )
Slide 18: Patent portfolio
a TTI THOS i Canaan 2540880 40508 3 | Rocaang Pomme tx Pana Doosan CaS we TSE TST i ‘European 0780960096 06/15/07 S chinese 2007800303286 6115/07 F [itesenciymat ster Cats feotated trom Mobiized Penipheral Blood Us. 61/266,825, T2AOe § [Bieter otter ct roto ron Penal Ds DSSS STD ED ae ra" > [ay Sra
Slide 19: Progressive Stem Cell Environment in China
Progressive Stem Cell Environment in China = Leverage platform to begin launching stem cell therapies in China in 2010 Different clinical/regulatory pathway vs. U.S. = Ministry of Health instead of SFDA More receptive of advanced therapeutics such as stem cell therapy Broader consumer acceptance of
Slide 20: China Stem Cells — 2010 Operational Targets
China Stem Cells — 2010 Operational Targets « Launch first stem cell therapeutic procedure in orthopedics in PRC = Wendeng launched in 1Q — revenue generation to start in summer 2010 = Open first anti-aging & cosmetic treatment center in Taiwan = Enhance launching adult stem cell collection and stor
Slide 21: Stem Cell Platform Summary
Stem Cell Platform Summary * Pioneer in autologous adult stem cell collection and storage * Collection network continues to expand in the U.S. and building infrastructure in China to enhance opportunity * Diverse mix of exclusive advanced adult stem cell technologies and applications = VSEL™ Technol
Slide 22: Financials
Financials 22
Slide 23: Key Financial Metrics
Key Financial Metrics NeoStem/CBH NeoStem, Inc. Proforma ‘ Three Months Ended Three Months Ended March 31, 2010 March 31, 2009 ( in 000's) Revenue Pharmaceuticals 15,775 12,691 ‘Stem cell and others 58 45 Total revenues 15,833 12,736 Gross profit 4,982 4,069 R&D expenses 1,300 227 Net cash used in o
Slide 24: Ownership & Equity Data (as of 6/1/10)
Ownership & Equity Data (as of 6/1/10) % Based on SEC % Outstanding | Beneficial Ownership Management & Directors (Excluding RimAsia) 45% 10.1% EET / Fullbright (Erye Managers and Minority Interest Holder) 6.8% 7.9% RimAsia 418% 45.9% Enhance Biomedical Holdings (Strategic Partner) 75% 13.9% Public
Slide 25: Management and Boards
Management and Boards 25
Slide 26: Key Executives
Key Executives Robin Smith, MD MBA © - ‘MD Yale; MBA ~ Wharton CEO &Chaimanofthe + Formerly President & CEO IP2M (HC multimedia), EVP & CMO HeathHelp (radiology management) Board + Trustee of NYU Medical Center, Chairman ofthe Board of NYU Hospital for Joint Diseases (through November 2008) ‘and Ste
Slide 27: Board of Directors
Board of Directors Robin Smith, MD, MBA CEO and Chairman ‘See Key Executives, Eric Wei Managing Partner, RimAsia Capital Partners BS Mathematics & Economics — Amherst College; MBA — Wharton Experience — Founder/Managing Partner of RimAsia Capital Partners (private equity); Peregrine Capital, Prudent
Slide 28: Scientific Advisory Board Members
Wayne Marasco, MD, PhD (Chairman) ory Board Members Associate Professor, Dept of Cancer and Immunology & AIDS at Dana-Farber Cancer Institute; Associate Professor of Medicine at Harvard Medical Schoo! Leading NeoStem’s independent research efforts and collaborations Douglas Losordo, Director of the
Slide 29: The Future
The Future 29
Slide 30: What's Next for NeoStem - Opportunities
2 What’s Next for NeoStem - Opportunities Si = License new stem cell technologies and pharmaceuticals = Stem cell — therapies, cells types, technologies = Pharmaceutical — generic drugs, biologics, brand or novel R&D drugs « Bolster intellectual property portfolio = Partner to commercialize therapie
Slide 31: Comparable Companies
Comparable Companies 31
Slide 32: Chinese Pharmaceutical Companies
2 Chinese Pharmaceutical Companies Si (Sin millions, except per share data and multiples) Price Revs (M) EVIRev EPS PIE Company Name Ticker 05/28/10 LTM_FY10E_LTM FY10___LTM_FY10E_LTM_FY10E 3 SBio SSRX $12.41 $51 $59 3.1x 26x $0.69 $0.64 21.0x 19.3x American Oriental Bioengineering AOB $3.10 $304 $3
Slide 33: Stem Cell Therapeutic Companies
Stem Cell Therapeutic Companies Adult (Autol Stem Cell Source See oe oUS NP xcut bran Hesue! Embryonic Mesenchymal System for , , Targeted Segments pel Therapeutics Therapeutics Targeted Geographies US: us. us 9 grap — LS. Le Other Pharmaceuticals None None en LTM Revenue $14 million $1 million $2 m
Slide 34: Cord Blood Stem Cell Banking Companies
e Cord Blood Stem Cell Banking Companies Sr ea = China Cord Blood (NYSE: CO) + Acquired by Pantheon China Acquisition Corp. in June 2009 + 9/30/09 LTM revenue = $34.3 million + Current enterprise value = ~$350 million (10.2x LTM revenue) = ViaCell, Inc. + Acquired by PerkinElmer, Inc. in October 200
Slide 35: Investment Highlights
Investment Highlights = Adult stem cell platforms offer high margin, near and long-term revenue opportunities = 2010 planned launches - orthopedic, anti-aging and cosmetic therapies in PRC and Taiwan » Future — innovative VSEL™ technology therapies for cardiovascular, stroke, wound healing « Leading
Slide 36: Contact Information
Contact Information NeoStem, Inc. Robin Smith, MD, MBA Chairman & CEO Phone: (212) 584-4174 Email: rsmith@neostem.com http:/Avww.neostem.com CCG Investor Relations, Inc. Lei Huang Account Manager Phone: (646) 833-3417 (New York) Email: lei.huang@ccgir.com http:/www.ccgir.com Crocker Coulson Presiden
Slide 37: NeoStem, Inc. ("NBS")
NEOSTEM, INC. (“NBS”) Investor Presentation oT